Novartis AG Triumphs in the Journey to Protect Vildagliptin Patent in Vietnam


Updated: Jul 04, 2024

2 clauses

KENFOX IP & Law Office

Verified user

KENFOX IP & Law Office

Law firm

Accepted payment methods

Key description

  • Novartis AG, a leading global pharmaceutical corporation, holds the patent for the active ingredient “Vildagliptin”, a crucial component in the treatment of type 2 diabetes. In Vietnam, this groundbreaking invention is protected under Patent No. 5529. Soon after, counterfeit products emerged in the market, significantly cheaper than the genuine product, causing confusion among consumers. Novartis




Please read our Terms of service and Privacy Policy carefully before using Lexub. By using Lexub, you agree to be bound by these documents.

Write review